HUP9903111A2 - Helyettesített 3,5-difenil-1,2,4-triazolok és fémkelátképzőként való gyógyászati alkalmazásuk - Google Patents

Helyettesített 3,5-difenil-1,2,4-triazolok és fémkelátképzőként való gyógyászati alkalmazásuk

Info

Publication number
HUP9903111A2
HUP9903111A2 HU9903111A HUP9903111A HUP9903111A2 HU P9903111 A2 HUP9903111 A2 HU P9903111A2 HU 9903111 A HU9903111 A HU 9903111A HU P9903111 A HUP9903111 A HU P9903111A HU P9903111 A2 HUP9903111 A2 HU P9903111A2
Authority
HU
Hungary
Prior art keywords
alkyl
halo
amino
alkoxy
optionally substituted
Prior art date
Application number
HU9903111A
Other languages
English (en)
Inventor
Pierre Acklin
René Lattmann
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9903111(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP9903111A2 publication Critical patent/HUP9903111A2/hu
Publication of HUP9903111A3 publication Critical patent/HUP9903111A3/hu
Publication of HU226232B1 publication Critical patent/HU226232B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya: (I) általánős képletű vegyületek és sóik, ezekelőállítása és gyógyszerkészítmény főrmájában való alkalmazása - eképletben R1 és R5 jelentése egyidejűleg vagy egymástól függetlenülhidrőgén, halőgén, hidrőxi-, alkil-, halőalkil-, alkőxi-, halőalkőxi-,karbőxil-, karbamőil-, N-alkilkarbamőil-, N,N-dialkil-karbamőil- vagynitril-csőpőrt, R2 és R4 jelentése egyidejűleg vagy egymástólfüggetlenül hidrőgén, adőtt esetben helyettesített alkanőil- vagyarőil-, vagy egy fiziőlógiai körülmények között eltávőlítható csőpőrt,R3 jelentése hidrőgén, alkil-, hidrőxialkil-, halőalkil-,karbőxialkil-, alkőxikarbőnilalkil-, R6R7=N-C(O)-alkil-, adőtt esetbenhelyettesített heterőaril- vagy heterőalkilcsőpőrt, R6 és R7 jelentéseegyidejűleg vagy egymástól függetlenül hidrőgén, alkil-,hidrőxialkil-, alkőxialkil-, hidrőxi-alkőxialkil-, aminőalkil-, N-alkil-aminőalkil-, N,N-dialkil-aminőalkil-, N-hidrőxi-alkil-aminő-alkil-, N,N-di-hidrőxi-alkil-aminő-alkil-csőpőrt vagy a kapcsőlódónitrődénatőmmal együtt azaciklűsős gyűrűt képez - őlyan betegségekellen, amelyek fémfelesleget őkőznak az emberi vagy állatiszervezetben, vagy amelyeket ilyen felesleg vált ki. ŕ
HU9903111A 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles, their production processes, their use as pharmaceutical metal chelators and pharamceutical compositions comprising said compositions HU226232B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (3)

Publication Number Publication Date
HUP9903111A2 true HUP9903111A2 (hu) 2000-01-28
HUP9903111A3 HUP9903111A3 (en) 2000-06-28
HU226232B1 HU226232B1 (en) 2008-07-28

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903111A HU226232B1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles, their production processes, their use as pharmaceutical metal chelators and pharamceutical compositions comprising said compositions

Country Status (37)

Country Link
US (3) US6465504B1 (hu)
EP (1) EP0914118B1 (hu)
JP (1) JP3541042B2 (hu)
KR (1) KR100616378B1 (hu)
CN (1) CN1146415C (hu)
AP (1) AP1127A (hu)
AR (1) AR007479A1 (hu)
AT (1) ATE226435T1 (hu)
AU (1) AU718037B2 (hu)
BG (1) BG64248B1 (hu)
BR (1) BR9709973A (hu)
CA (1) CA2255951C (hu)
CY (2) CY2429B1 (hu)
CZ (1) CZ291470B6 (hu)
DE (3) DE122007000020I1 (hu)
DK (1) DK0914118T3 (hu)
ES (1) ES2187785T3 (hu)
FR (1) FR06C0049I2 (hu)
GE (1) GEP20084355B (hu)
HK (1) HK1020530A1 (hu)
HU (1) HU226232B1 (hu)
IL (1) IL127212A0 (hu)
LT (1) LTC0914118I2 (hu)
LU (1) LU91291I2 (hu)
MY (1) MY129541A (hu)
NL (1) NL300248I2 (hu)
NO (3) NO317180B1 (hu)
NZ (1) NZ333308A (hu)
OA (1) OA10946A (hu)
PL (1) PL194758B1 (hu)
PT (1) PT914118E (hu)
RU (1) RU2208010C2 (hu)
SI (1) SI0914118T1 (hu)
SK (1) SK284319B6 (hu)
TR (1) TR199802693T2 (hu)
TW (1) TW533205B (hu)
WO (1) WO1997049395A1 (hu)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
BRPI0417759A (pt) * 2003-12-19 2007-04-10 Novartis Ag combinação de (a) n-{5-[4-(metil-piperazino-metil)-benzoilamido]-2-metilf enil}-4-(3-piridil)-2-pirimidina-amina e (b) pelo menos um inibidor de hipusinação e o seu uso
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
DK1843771T3 (da) * 2005-01-28 2012-01-16 Novartis Ag Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
KR20070101314A (ko) * 2005-02-10 2007-10-16 노파르티스 아게 약물 처리과정을 개선하기 위한 방법
MX2007015085A (es) * 2005-05-31 2008-01-17 Novartis Ag Tratamiento de enfermedades del higado en donde el hierro juega un papel importante en patogenesis.
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
PL1945272T3 (pl) 2005-11-01 2014-03-31 Novartis Ag Sposób prowadzenia scyntygraffi
BRPI0711385A2 (pt) * 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
MX2008014837A (es) 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
CL2007002026A1 (es) 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
AU2007280639A1 (en) * 2006-08-04 2008-02-07 Novartis Ag Treatment of endocrine dysfunction using iron chelators
BRPI0720793A2 (pt) 2006-11-29 2014-03-11 Novartis Ag SAIS E FORMAS CRISTALINAS DE ÁCIDO 4-[3,5-BIS(2-HIDRÓXI FENIL)-[1,2,4]tRIAZOL-1-IL]BENZOICO
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
AU2008250041A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
US20090142395A1 (en) 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
TWI488624B (zh) 2008-09-22 2015-06-21 Nat University Corp Asahikawa Medical College 鐵螯合劑、其製造方法及鐵離子之定量、捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
MX2011009735A (es) 2009-03-19 2011-10-19 Los Angeles Biomed Res Inst Composiciones de vacuna y metodos para el tratamiento de mucormicosis y otras enfermedades fungicas.
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
US8772503B2 (en) 2009-12-07 2014-07-08 Mapi Pharma Ltd. Processes for the preparation of deferasirox, and deferasirox polymorphs
EP2929877A1 (en) 2010-07-08 2015-10-14 ratiopharm GmbH Oral dosage form of deferasirox
EP2632907B1 (en) * 2010-08-25 2015-10-14 Davuluri, Ramamohan Rao Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox
PE20170468A1 (es) * 2010-10-01 2017-04-26 Cipla Ltd Composicion farmaceutica que comprende deferasirox
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
EP2766049A1 (en) 2011-10-14 2014-08-20 Photocure ASA Photodynamic diagnosis of abnormalities of the epithelial lining of the oesophagus with the means of a 5-ala ester
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) * 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
PL2964659T3 (pl) * 2013-03-06 2018-04-30 Biocon Limited Sposób wytwarzania deferazyroksu
SI2964202T1 (sl) * 2013-03-08 2019-02-28 Novartis Ag Peroralne formulacije deferasiroksa
ZA201403276B (en) * 2013-05-10 2015-07-29 Cipla Ltd Low dose pharmaceutical composition
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
PT2946771T (pt) 2014-05-20 2019-06-27 Sanovel Ilac Sanayi Ve Ticaret As Formulação de comprimido dispersível em água compreendendo deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
CN108290878B (zh) 2015-10-23 2022-04-26 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
NO2006017I1 (no) 2006-12-18
FR06C0049I2 (fr) 2007-04-27
NO2006017I2 (no) 2011-07-04
ES2187785T3 (es) 2003-06-16
LTC0914118I2 (lt) 2018-12-27
JP2000507601A (ja) 2000-06-20
BG64248B1 (bg) 2004-07-30
PL330119A1 (en) 1999-04-26
AP9801407A0 (en) 1998-12-31
US6465504B1 (en) 2002-10-15
DE69716602T2 (de) 2003-06-26
CY2007005I2 (el) 2018-12-12
CY2007005I1 (el) 2010-07-28
DK0914118T3 (da) 2003-02-24
NO986024L (no) 1998-12-21
BG103003A (en) 1999-09-30
US6723742B2 (en) 2004-04-20
KR100616378B1 (ko) 2006-08-28
CA2255951C (en) 2006-10-10
NL300248I1 (nl) 2007-02-01
KR20050098029A (ko) 2005-10-10
NZ333308A (en) 2000-05-26
RU2208010C2 (ru) 2003-07-10
CA2255951A1 (en) 1997-12-31
CN1146415C (zh) 2004-04-21
DE122007000020I2 (de) 2010-12-30
CZ291470B6 (cs) 2003-03-12
DE122007000020I1 (de) 2007-05-24
US20030069273A1 (en) 2003-04-10
HK1020530A1 (en) 2000-05-12
SK178598A3 (en) 1999-06-11
NL300248I2 (nl) 2007-03-01
ATE226435T1 (de) 2002-11-15
PL194758B1 (pl) 2007-07-31
WO1997049395A1 (en) 1997-12-31
NO2018014I1 (no) 2018-04-17
EP0914118A1 (en) 1999-05-12
GEP20084355B (hu) 2008-04-29
AU718037B2 (en) 2000-04-06
SI0914118T1 (en) 2003-04-30
HUP9903111A3 (en) 2000-06-28
US6596750B2 (en) 2003-07-22
BR9709973A (pt) 1999-08-10
AR007479A1 (es) 1999-10-27
NO986024D0 (no) 1998-12-21
NO2018014I2 (no) 2018-11-19
OA10946A (en) 2003-02-27
SK284319B6 (sk) 2005-01-03
IL127212A0 (en) 1999-09-22
PT914118E (pt) 2003-02-28
JP3541042B2 (ja) 2004-07-07
HU226232B1 (en) 2008-07-28
NO317180B1 (no) 2004-09-06
AP1127A (en) 2002-12-06
CN1223579A (zh) 1999-07-21
TR199802693T2 (xx) 1999-05-21
LTPA2007001I1 (lt) 2018-06-25
CZ427298A3 (cs) 1999-03-17
MY129541A (en) 2007-04-30
LU91291I2 (fr) 2007-01-29
DE69716602D1 (de) 2002-11-28
LU91291I9 (hu) 2018-12-27
TW533205B (en) 2003-05-21
US20030203954A1 (en) 2003-10-30
AU3262997A (en) 1998-01-14
CY2429B1 (en) 2004-11-12
FR06C0049I1 (hu) 2007-03-09
EP0914118B1 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
HUP9903111A2 (hu) Helyettesített 3,5-difenil-1,2,4-triazolok és fémkelátképzőként való gyógyászati alkalmazásuk
PL324795A1 (en) Application of adamantane derivatives in treating internal ear diseases
MY141457A (en) 4-mercaptopyrrolidine derivates a farnesyl transferase inhibitors
CA2189131A1 (en) Use of pteridine derivatives as no-synthase inhibitors
TR199801244T2 (xx) Herpese kar�� �zellikler ta��yan fenil tiyazol t�revleri.
GB0005251D0 (en) Therapeutic compounds
CA2107014A1 (en) Therapeutic Agent for Parkinson's Disease
CA2230082A1 (en) Amide compounds and use thereof
MX9702382A (es) Nuevos derivados de pirimidona con actividad antifungica.
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
NO304379B1 (no) 11,21-bisfenyl-19-norpregnan-derivater, anvendelse derav og farmas°ytiske preparater inneholdende slike derivater
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
NZ236034A (en) Pharmaceutical compositions containing imidazole derivatives; topical compositions for treating glaucoma
EP1140900A4 (en) PYRAZOLE COMPOUNDS AND USE OF SUCH COMPOUNDS
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
IT1247509B (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
ES8402309A1 (es) Procedimiento para la preparacion de derivados de penem.
NO944917D0 (no) Anvendelse av 2-fenyl-3-aroyltiofener for inhibering av eggstokkdysgenese, forsinket pubertet eller seksuell infantilisme
PL326554A1 (en) Derivatives of amine and thiourea and inhibitors of nitrogen oxide synthase
RU94031479A (ru) Новое применение производных аминокислот, способ лечения, фармацевтическая композиция
DE69427807D1 (de) Hemmung von Hirsutismus und Alopecia bei Frauen
ES2116880A1 (es) Farmacos y composiciones farmaceuticas para su uso en el tratamiento de enfermedades.
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
MX9704548A (es) Compuestos peptidomesticos antiherpes.
TW349099B (en) Apovincamine derivatives and the pharmaceutical composition thereof

Legal Events

Date Code Title Description
AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: DEFERASIROX AND PHARMACEUTICALY ACCEPTABLE; REG. NO/DATE:; FIRST REG.: EU EU/1/06/356/001-006 20060828

Spc suppl protection certif: S0800006

Filing date: 20080623

Expiry date: 20170624

Free format text: PRODUCT NAME: DEFERASIROX AND PHARMACEUTICALY ACCEPTABLE FIRST REGISTRATION NO/DATE: EU*EU/1/06/356/001-006*2006.08.28*

Spc suppl protection certif: S0800006

Filing date: 20080623

Expiry date: 20170624

Effective date: 20080623

FG4S Grant of supplementary protection certificate

Free format text: PRODUCT NAME: DEFERASIROX AND PHARMACEUTICALY ACCEPTABLE; REG. NO/DATE:; FIRST REG.: EU EU/1/06/356/001-006 20060828

Spc suppl protection certif: S0800006

Filing date: 20080623

Expiry date: 20170624

Extension date: 20210828